Dosing chart / Longevity & immune
MOTS-c vs SS-31
Dose, schedule, route and approval status side by side.
Reference only, not medical advice. Doses marked FDA-approved come from the US prescribing label. Doses marked Not approved are ranges reported from small studies or community use and have not been established as safe or effective in humans. Check anything here with a licensed clinician before acting on it. Read the full disclaimer.
| MOTS-c | SS-31 | |
|---|---|---|
| Status | Not approved | FDA-approved |
| Also known as | – | elamipretide, Forzinity |
| Typical dose | 5–10 mg | 40 mg |
| How often | 2–3 times weekly | Daily |
| Schedule | Two or three times a week. | Once daily. |
| Daily equivalent | ≈ 1.4–4.3 mg/day | 40 mg/day |
| Route | Subcutaneous | Subcutaneous |
| Duration | 4–8 weeks reported | Ongoing |
| Notes | Mitochondria-derived peptide studied mainly in mice. Doses are community-reported. | Received accelerated FDA approval in September 2025 for Barth syndrome in patients weighing at least 30 kg. Use for general longevity is unproven. |
This page sets the two chart entries next to each other. It does not say which is better or whether either is right for you. Read member experiences on the MOTS-c and SS-31 pages.
Advertisement